금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
1 S&P 500 Stock Worth Investigating and 2 We Turn Down
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a ...
XMAG Is Outperforming the S&P 500 in 2026 as the Magnificent Seven Stall
The fund that was supposed to track the market's most powerful stocks is getting beaten by a fund bu...
Global policy uncertainty hits multi-year high, Goldman Sachs says
Groupe Dynamite GAAP EPS of C$0.45, revenue of C$310.58M
Pacer’s Dividend Multiplier ETF Pays 400% of the S&P 500’s Dividend, With a Catch Most Investors Don’t Notice
Income-based investors, such as retirees, often avoid high growth investments for (2) reasons: Capital risk due to market volatility Lack of income production The S&P 500 is a perfect example of this. ...
This Vanguard ETF Is Quietly Outpacing the S&P 500 in 2026 and Costs Just 0.04 Percent
The Vanguard Growth ETF (NYSEARCA:VUG) trades near $86 after a brutal five-day stretch that lopped 4.5% off the price. Year to date, VUG is up 6.2%, currently trailing the S&P 500’s 8.4% gain as megac ...
Nebius Soars 124% in 3 Months: Should You Buy, Hold, or Fold?
NBIS has surged 123.6% in three months as AI infrastructure, revenue growth and capacity expansion fuel momentum, but can it sustain the run?
VMI Stock Rallies 32% in 3 Months: What's Driving the Upside?
Valmont Industries' rally is backed by Infrastructure margin gains, utility demand, backlog growth and raised fiscal 2026 guidance.
SpaceX IPO: What Your $5,000 Investment Could Be Worth
The company's valuation prices in lofty growth expectations.
This Global ETF Is Beating the S&P 500 in 2026 -- but There's 1 ETF That I Like Better
Diversification might be a better long-term bet than dividends.
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500’s 9.3% gain. This might have investors contemplat ...
Hairy stuff: e.l.f. Beauty looks to disrupt a new category
Outlook gains as wet AMD therapy reconsidered for FDA review
Software stocks lose their aura on agentic AI disruptive threat